SCID is a heterogeneous group of disorders characterized by defective T cell and B cell function. Eczematous and morbilliform eruptions are common, and graft-versus-host disease (GVHD) due to maternal engraftment has been documented. We sought to better characterize SCID-related cutaneous disease observed prior to BMT and to compare the eruption to conventional GVHD. Medical records of 51 patients with SCID treated between 1982 and 1999 were reviewed. Ten of 51 (20%) had rash and evidence of maternal engraftment prior to BMT (study group). Eleven of 51 (22%) had no rash or evidence of engraftment pre-BMT but developed GVHD following transplant (control group). Skin biopsies were available for review for 8/10 of the study group and for 8/11 of the control group. Cutaneous findings consisted of a scaling, erythematous maculopapular eruption spread widely over the trunk and extremities, with near-erythroderma in some patients. Microscopically, biopsies from the study group differed significantly from controls. Key differences included parakeratosis (P р 0.01), psoriasiform hyperplasia (P р 0.04) and spongiosis (P р 0.04). The dermatopathologic findings of transplacental GVHD differ from the pattern of post-transplant GVHD. A 'psoriasiform-lichenoid-spongiotic' pattern with necrotic keratinocytes should trigger consideration of SCID and maternal engraftment in the dermatopathologic evaluation of eruptions of infancy. Bone Marrow Transplantation (2001) 28, 227-233. Keywords: severe combined immunodeficiency disease (SCID); bone marrow transplant (BMT); graft-versus-host disease (GVHD); maternal engraftment Severe combined immunodeficiency diseases (SCIDs) are a heterogeneous group of genetic disorders characterized by deficiency of both T and B cell functions. The mode of
inheritance can be autosomal recessive or X-linked. These disorders are rare, with a frequency ranging from one in 50 000 to one in 500 000 births. 1 Clinical signs and symptoms commonly manifest by 6 months of age and include failure to thrive, oral thrush, candidal diaper rash, recurrent respiratory infections, cutaneous graft-versus-host disease (GVHD) and oral and genital ulcerations. The nonspecific clinical findings and the significant degree of variability among patients often complicate and delay the diagnosis. The profound lack in immune function leads to infections usually fatal in infancy unless the immune system can be reconstituted. 1 Currently, hematopoietic stem cell transplantation from a variety of sources including bone marrow, peripheral or umbilical cord blood is the primary modality of treatment of SCID, 2 although the early results of gene therapy are encouraging. 3 The major cutaneous manifestations of SCID are skin and mucosal infections, eczematous rashes and GVHD. Patients with SCID are frequently engrafted with transplacentally-derived maternal T lymphocytes. Although maternal T cells in SCID rarely induce lethal, systemic, multiorgan GVHD, cutaneous manifestations of GVHD can be striking. Maternal engraftment may also be asymptomatic. 4 It has been postulated that maternal T cells can prevent engraftment of bone marrow transplants from nonmaternal donors, in particular when HLA-mismatched (haplocompatible) T cell-depleted transplants are used. Because engraftment is incomplete, in most instances maternal cells fail to protect the host against opportunistic infections. 5 In contrast to the well-characterized histopathologic features of GVHD due to BMT, those due to transplacental maternal engraftment are less well studied. Some reports have identified features indistinguishable from post-transplant GVHD, but the reported microscopic features have not been consistent. [6] [7] [8] We evaluated the clinicopathologic characteristics of cutaneous GVHD in a group of SCID patients with evidence of maternal engraftment prior to bone marrow transplant. We also sought to determine if the manifestations of GVHD in these patients were indeed distinct from the well characterized forms of GVHD associated with either bone marrow transplantation, the transplantation of other organs or the transfusion of nonirradiated blood. Patients with SCID but no evidence of maternal engraftment pre-BMT who developed a rash after BMT were used as a control group.
Methods

Patients
The medical records of 51 patients with a diagnosis of SCID who received a BMT at the University of California, San Francisco, Pediatric Bone Marrow Transplant Division between 1982 and 1999 were reviewed. Ten of these patients were found to have evidence of maternal engraftment and rash prior to BMT (group A). An additional 11 did not have evidence of maternal engraftment or a rash pre-BMT but developed rash post BMT (group B).Two patients were found to have evidence of maternal engraftment pre-BMT without rash and thus were excluded from the study. Four patients did not have evidence of maternal engraftment pre-BMT but had a rash pre-BMT. These patients did not have histopathology and were thus also excluded. Twenty-four others, who had neither engraftment nor rash before or after BMT, were also excluded from the study.
Data acquisition
Patients of white, hispanic, native American, Middle Eastern and Asian background were represented in this study. After 1989, a diagnosis of maternal engraftment was made based on variable number of tandem repeat (VNTR) analysis, also referred to as microsatellite analysis and/or in situ hybridization. VNTR probes give strong hybridization signals allowing for earlier detection of chimerism as well as detection of small numbers of cells. Prior to 1989, methods for detecting maternal engraftment included testing for blood group antigens, polymorphic blood proteins and karyotyping. However, these tests are often not sufficiently sensitive to detect engraftment. [9] [10] [11] Maternal engraftment was diagnosed on clinical grounds, which in addition to skin eruption, included failure to thrive, hepatosplenomegaly and a lack of any other explanation for these findings in the presence of the diagnosis of SCID. In addition, histopathology with features of GVHD was also used as supporting evidence for cases prior to the late 1980s (3/10 in group A).
At diagnosis, the patients in group A had virtual absence of T and B cell numbers and function. The majority of patients in group A (70%) were T-B-with the remaining 30% being T−B+. Two of the T−B+ phenotypes were Xlinked by familial inheritance pattern. In group B, 55% were T−B− and 45% were T−B+. Two of the T−B+ patients in group B were adenosine deaminase (ADA) deficient. Following medical record review, all available skin pathology was reviewed for both groups. Pathology was available for 8/10 in group A and 8/11 in group B. The slides were read by a dermatopathologist who graded all subjects according to standard histologic criteria. The pathologist was aware that all patients had a diagnosis of SCID and had received BMT. He was also aware of which group of patients had a diagnosis of maternal engraftment prior to BMT but was blinded to the prior skin biopsy diagnosis. Chi-square statistical analysis was performed on the histopathological parameters.
Results
Representative cutaneous lesions are described in Tables 1  and Table 2 and illustrated in Figure 1 . The severity ranged from fine erythematous maculopapular lesions involving the trunk and extremities to total erythroderma with alopecia. In addition to rash, virtually all patients had oral thrush and nonspecific symptoms of fever, cough, diarrhea and failure to thrive. Treatment regimens for cutaneous lesions ranged from topical creams and steroids to systemic immunosuppression. Conditioning protocols ranged from none to combinations of systemic immunosuppressives. Seven of the eight patients in group A had rashes that were unresponsive to multiple therapies but resolved after BMT. One patient had a rash that resolved with topical ketoconazole therapy prior to BMT, but did not have a skin biopsy performed.
The histopathological results are shown in Table 3 and illustrated in Figures 2 and 3 . Of the eight patients in group A who had skin biopsies, only three had a previous histopathologic diagnosis of GVHD. Two had been diagnosed as subacute spongiotic dermatitis, two had vacuolar interface dermatitis and one had a diagnosis of nonspecific dermatitis. Group B was utilized as a control group and of the eight patients with skin biopsies, one had a prior histopathologic diagnosis of GVHD, one had interstitial dermatitis, one had interface dermatitis, one had vascular ectasia and four had superficial perivascular dermatitis. The parameters that showed statistical significance were psoriasiform hyperplasia (P Ͻ 0.04), parakeratosis (P Ͻ 0.01), spongiosis (P Ͻ 0.04), necrotic keratinocytes (P Ͻ 0.04) and lichenoid infiltrate (P Ͻ 0.04). A perifollicular infiltrate was observed in 38% of patients in group A and in none of group B, which is borderline insignificant (P = 0.055). The density of lymphocytes and other inflammatory cells did not show statistical significance between group A and group B. However, the very small number of patients in these two groups may have resulted in a lack of statistical power to detect some of the differences that could exist between them.
Discussion
Our study indicates that maternal engraftment due to the transplacental transfer of T cells is indeed a common phenomenon in patients with a diagnosis of SCID. Eighty-three percent of those engrafted develop a skin eruption as a manifestation of maternal engraftment that is clinically similar to that seen in classic GVHD. However, the cutaneous histopathology in maternally engrafted patients is distinct from the patients with SCID who developed a rash post BMT (group B), and also distinct from classical cutaneous GVHD after transplant for other diseases. Moreover, the definitive diagnosis of maternalfetal GVHD can be problematic because the clinical and histological features are difficult to distinguish from other con- Resolved with erythematous rash CY200 immunosuppression post BMT ATG80 ATG80 = anti-thymocyte globulin 80 mg/kg; ATG90 = anti-thymocyte globulin 90 mg/kg; BU14 = busulphan 14 mg/kg; BU16 = busulphan 16 mg/kg; CY120 = cyclophosphamide 120 mg/kg; CY200 = cyclophosphamide 200 mg/kg; NA = not available. Normal ranges: Total lymphocyte count (2-14 × 10 9 /l), total CD3 count (0.657-2.37 × 10 9 /l), CD3% (53-84%). cyclosporine dose arms and face ATG80 = anti-thymocyte globulin 80 mg/kg; ATG90 = anti-thymocyte globulin 90 mg/kg; BU14 = busulphan 14 mg/kg; BU16 = busulphan 16 mg/kg; CY120 = cyclophosphamide 120 mg/kg; CY200 = cyclophosphamide 200 mg/kg; NA = not available. Normal ranges: Total lymphocyte count (2-14 × 10 9 /l), total CD3 count (0.657-2.37 × 10 9 /l), CD3% (53-84%).
ditions that can be seen in SCID patients, such as drug eruptions, exanthems or eczema. In addition, unlike most patients with SCID who have profound lymphopenia, the peripheral blood lymphocyte count may be normal or even elevated in transplacentally engrafted infants because of circulating maternal cells. Maternal engraftment secondary to transplacental transfer of T lymphocytes was observed in 24% (12/51) of all patients with SCID in this series, comparable to the previously reported figure of 25% by Thompson et al. 12 It is possible that a greater percentage was engrafted and that the relative insensitivity of earlier methods precluded accurate detection. Although not utilized in our study, current technology involving locus-specific probes has enabled the retrospective testing of patients for engraftment post BMT. 10 The skin eruptions of GVHD due to maternal engraftment are clinically similar to those seen in patients with GVHD after BMT. These classic lesions have been well characterized and involve an acute phase with morbilliform erythema, papular dermatitis and diffuse erythroderma. The face, neck, palms and soles are usually the initial sites, prior to a generalized eruption. In severe cases, diffuse bullae or toxic epidermal necrolysis is observed. Rashes in our maternally engrafted patients spanned this morphological array. Cutaneous findings ranged from transient morbilliform to total erythroderma with alopecia. Typically, these rashes were refractory to topical treatment prior to BMT and resolved with systemic immunosuppression shortly after BMT.
The histopathology of GVHD due to maternal engraftment differs significantly from that due to BMT. As noted, GVHD secondary to maternal engraftment is characterized by psoriasiform hyperplasia with parakeratosis and variable spongiosis, in contrast to the vacuolar interface pattern observed in conventional GVHD, yet necrotic keratinocytes (suggesting an element of keratinocytotoxicity) are identifiable in both diagnostic groups. 13 The consistent findings of psoriasiform hyperplasia and prominent spongiosis in particular are distinctive and can easily cause diagBone Marrow Transplantation nostic confusion, since these are seen only rarely in classic GVHD.
Lerner et al 14 proposed the following grading scheme of GVHD: grade I, characterized by focal or diffuse vacuolar degeneration (of epidermal basal cells); grade II, characterized by vacuolar degeneration with dyskeratosis (keratinocyte necrosis); grade III, characterized by grade II changes plus subepithelial clefting; and grade IV, characterized by confluent epithelial necrosis. Spongiosis is not typically a prominent feature of GVHD due to BMT but, when present, is usually found in patients with grades III/IV disease, not grades I and II. 15 Our findings of a statistically significant difference in the presence of spongiosis between group A and group B patients supports the conclusion that GVHD due to maternal engraftment has features which are distinct from that due to BMT.
Graft-versus-host disease due to maternal engraftment should always be suspected in a neonate with erythroderma. The differential diagnosis of neonatal erythroderma is large including immunodeficiency disorders, infections, viral exanthems, drug eruptions, congenital psoriasis and several forms of ichthyosis. 16 Microscopically, viral exanthems and certain drug eruptions can be difficult to distinguish from acute GVHD. Viral exanthems are characterized by a vacuolar interface pattern, but it is often subtle and necrotic keratinocytes are few compared to GVHD. Drug eruptions, especially drug-induced erythema multiforme (EM) is even more difficult as there are no well-defined histologic criteria to distinguish it from acute GVHD. Involvement of follicular epithelium is more common in GVHD but can be seen in EM. Fortunately, the clinical appearance of GVHD and EM are easily distinguished. Rarely, GVHD in neonates may be confused with ichthyosiform erythroderma, seborrheic dermatitis, atopic dermatitis, psoriasis, pityriasis rubra pilaris, so-called Leiner's disease, Langerhans cell histiocytosis, nutritional deficiencies of zinc, biotin, and essential fatty acids, and even widespread congenital syphilis. However, clinicopathologic correlation is often sufficient to distinguish GVHD from these entities.
The differentiation of GVHD caused by maternal engraftment and Omenn's syndrome deserves special consideration. Omenn's syndrome is an autosomal recessive form of combined immunodeficiency with a gene defect that has been mapped to chromosome 11. 17 Typical features include a widespread skin eruption, alopecia, lymphocytosis, hepatosplenomegaly, lymphadenopathy, recurrent infections and failure to thrive. These features can also be seen in some cases of maternally induced GVHD. However, in Omenn's syndrome the degree of eosinophilia, lymphadenopathy and hepatosplenomegaly are usually more pronounced. 16 Some reported cases of Omenn's syndrome have had microscopic features which strongly resemble those of our maternally engrafted patients. 7 In addition, many either did not mention or did not have documentation of maternal engraftment using current, more sensitive methods of detection. Thus, some patients reported as having 'Omenn's syndrome' may actually have had maternally-induced GVHD.
Three of our patients had many features of Omenn's syndrome. Patient 10 presented with a total body erythematous rash, fever, hepatomegaly and eosinophilia at 1 month of Figure 2 A low magnification view of the eruption associated with maternal engraftment shows slight psoriasiform epidermal hyperplasia, focal spongiosis and parakeratosis, and a fairly dense papillary dermal infiltrate. This 'lichenoid-psoriasiform' pattern contrasts distinctly to the pattern of conventional GVHD, in which the epidermis usually displays vacuolar alteration of the lower most epidermis in association with a sparse superficial dermal infiltrate. age. He was diagnosed with SCID in 1983, and laboratory studies available at this time may not have been sensitive enough to detect maternal engraftment. Patient 7 presented at age 5 months with a fine erythematous maculopapular rash over his trunk and extremities, lymphadenopathy, hepatomegaly and eosinophilia, but was found to be maternally engrafted by VNTR analysis. Patient 2 presented at 4 months with a generalized eczematous rash accompanied by lymphadenoapthy, hepatosplenomegaly, and eosinophilia and was also found to be maternally engrafted by VNTR analysis. In spite of conclusive evidence of maternal engraftment in patients 2 and 7 and high clinical suspicion in patient 10, coexistent Omenn's syndrome is not necessarily excluded since none had specific gene testing for Omenn's syndrome.
The explanation for the differences in cutaneous GVHD in group A and classical GVHD is probably multifactorial. One difference may be the limited T cell receptor diversity of transplacentally acquired maternal T cells in SCID. Thus, Knobloch et al 5 demonstrated that maternal T cells express a profoundly reduced heterogeneity in their TCR repertoire by using a panel of mAb specific for TCR V region epitopes. This lack of heterogeneity may correlate with the distinct histopathological findings in those patients receiving maternal T cells transplacentally, as opposed to via BMT. Similarly, T cell functions may be limited, corre-sponding to the number of maternal cells that cross the placenta. Unlike the better documented and more abundant presence of fetal lymphocytes in the circulation of the mother, it has been suggested that only trace amounts of maternal cells enter the fetus. Thus, the distinct features of cutaneous GVHD in patients with maternal engraftment pre-BMT may be due to functional characteristics of the T cells or a functionally limited repertoire of T cells when these patients are engrafted transplacentally.
The early diagnosis of SCID is critically important since early BMT can provide a definitive cure and avoid severe morbidity or mortality from the immunodeficiency itself. The clinician should consider the diagnosis of SCID when confronted with a widespread cutaneous eruption and associated pathology as described above. This study highlights the diagnostic value of skin histopathology in infants with widespread rashes along with other symptoms such as thrush, diarrhea and failure to thrive. Recognizing the clinicopathologic findings described in this study may aid in earlier diagnosis of SCID with maternally induced GVHD, which in turn can lead to earlier treatment.
